Panacos Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
PANC Panacos Pharmaceuticals Inc
CARR Carrier Global Corp
BRK.B Berkshire Hathaway Inc
PRA ProAssurance Corp
CAJFF Canon Inc
INSG Inseego Corp
LVRLF CordovaCann Corp
SRNE Sorrento Therapeutics Inc
JWN Nordstrom Inc
BKKXF Bangkok Expressway and Metro PCL
Go

Health Care : Biotechnology |
Company profile

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Price
Delayed
$0.0001
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 0 shares is on pace to be much lighter than PANC's 10-day average volume of 1,667 shares.

0

Company Profile

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
0.05x
Price/Book (MRQ)
0.00x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

No short interest available.

Share Information

PANC is in a share class of common stock
Float
53.6M
Shares Outstanding
53.6M
Institutions Holding Shares
0
0.00%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Jeremy Hayward-SurryChmn.
  • Alan William DuntonCEO
  • David E. MartinSr.VP
  • Robert B. Pelletier
  • Tom LateganVP

Address

  • 134 Coolidge Ave
  • Watertown, MA 02472-2815
  • Phone: (617) 926-1551
  • Fax: (302) 655-5049

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.